If you liked this article you might like

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
American Companies, Even Those Critical of Trump, Gave Big Bucks to Inauguration
Gilead, Pfizer, AbbVie Win From Lilly's Loss
Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis